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Abstract:  
Purpose: The use of patient reported outcome (PRO) measures in clinical practice is increasing. 
Following the creation of a ‘User’s Guide to Implementing PRO Assessment in Clinical Practice’ by 
the International Society for Quality of Life Research (ISOQOL), volunteers from ISOQOL sought to 
create a Companion Guide to assist health care providers with the scientific and practical 
considerations involved in implementing and using PRO measures in clinical care by using 
information from real-world case studies. This paper summarizes the key issues presented in the 
Companion Guide.  
Methods: Ten respondents who were members of the ISOQOL’s CP-SIG and worked in various 
clinical areas, participated in a survey or telephone interview. Participants were from Canada (n=2), 
Denmark (n=1), England (n=2), Holland (n=1) and the United States (n=4).  
Results: Based on the information provided by respondents, a Companion Guide was produced, 
organized according to the nine questions presented in the User’s Guide. An additional section for 
key take-home messages was also provided. This guide provides examples of issues and 
considerations related to the implementation of PRO measures in clinical practice. 
Conclusions: Respondents provided insight into their experiences and emphasized that PRO 
initiatives were likely to be more successful if there is purposeful, designed integration into clinical 
practice, meaningful substantive engagement with all stakeholders and access to necessary 
organizational resources. The ability to leverage existing technology as well as realistic and 
stakeholder consensus-driven expectations for planning and timing were also key to the successful 
implementation of PRO measures. 
Keywords: Clinical practice, Patient-reported outcome, PRO, Guidelines, ISOQOL, Implementation. 
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Background: 
Patient reports on self-defined daily functioning and well-being can be used in conjunction with 
other clinical information to inform management of patient care. Patient reported outcome (PRO) 
measures are increasingly being used in clinical practice to support patient care by helping providers 
monitor health outcomes and health-related quality of life (HRQOL), track patient progress, enhance 
communication with patients, and improve patient satisfaction with care received [1,2]. However, 
previous literature suggests that healthcare providers often experience significant practical 
challenges – such as administrative burden, cost of use, problems with PRO interpretation, and 
skepticism around clinical meaning – to successfully integrating PRO assessment into clinical practice 
workflows [3-6]. Following discussions by ISOQOL members about these challenges, a ‘User’s Guide 
to Implementing Patient-Reported Outcomes Assessment in Clinical Practice (the “User’s Guide”)’ 
was created in 2011 by the International Society for Quality of Life Research (ISOQOL) [7]. The User’s 
Guide poses nine questions that should ideally be addressed when implementing PROs in clinical 
settings (see Table I below).  
Table I: Nine Core Questions from ISOQOL's User's Guide 
(1) What are the goals for collecting PRO data in clinical practice and what resources are 
available?  Which key barriers require attention? 
(2) Which groups of patients will be assessed? 
(3) How will the PRO measures be selected? 
(4) How often will the PRO measures be administered? 
(5) How will the PRO measures be administered and scored? 
(6) What tools are available to aid in score interpretation and how will scores requiring 
clinical follow-up be determined? 
(7) When, where, how, and to whom will results be presented? 
(8) What will be done to respond to issues identified through the PRO assessment? 
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(9) How will the value of PRO assessment be evaluated? 
 
Following this, in 2013, ISOQOL members attending the clinical practice special interest group (CP-
SIG) meeting discussed the need for further aid in understanding the realities, challenges and 
opportunities associated with using PRO measures in clinical practice. They identified that assistance 
could be provided through the sharing of real-world experiences. Despite the already existing User’s 
Guide, there was a clear need for this guidance to be enhanced through the provision of case studies 
detailing current PRO implementations in clinical practice. This would thus assist health care 
providers with the operational issues involved in implementing and using PRO measures in clinical 
care.  
In response to this need, members of the CP-SIG were invited to partake in either a survey or an 
interview. As part of this, members were encouraged to share their own experiences of employing 
PRO measures within clinical practice settings. The findings were then presented in a Companion 
Guide, compiling information from real world PRO implementation that ultimately enabled the 
User’s Guide to be brought “to life”. This Companion Guide can be accessed on the ISOQOL website 
at http://www.isoqol.org/research-publications-landing-page/isoqol-publications. This is a key 
resource that accompanies the User’s Guide to assist in optimal use of PRO measures in clinical care. 
This paper provides a brief overview of the experiences and challenges discussed by participants 
when implementing PRO measures, alongside the key lessons that were learned.   
Methods:  
Study design and participants:  
The core working group of ISOQOL CP-SIG volunteers (KH, LN, TE, EC, SPM) initially developed a 
template based on the nine questions in the User’s Guide. This template sought to inform the 
collection of real-life case studies with which to illuminate pragmatic experience and guidance for 
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PRO implementation and use. In early 2014, the working group sent an open invitation to members 
of ISOQOL’s CP-SIG to share their experiences of using PRO measures in clinical practice by 
participating in either a survey or telephone interview.   
Ten CP-SIG members agreed to take part in the survey or interview and provided written consent to 
participate. Six of the respondents in the sample worked within academic hospital settings and four 
worked within a university. Respondents were located in a range of countries including, Canada 
(n=2), Denmark (n=1), England (n=2), Holland (n=1), and the United States (n=4). The participants 
worked with a range of patient populations and specialties, including General Practice/Pediatrics 
(n=2), Occupational Medicine (n=1), Oncology (n=2), Lung/Heart Transplantation (n=1), Orthopedics 
(n=1), Rheumatology (n=1) and Chronic Pain (n=1). Below is a list of the participating respondent 
sites (Table II).  
Table II: Participant responding sites 
Case Study # Population Country 
#1 Chronic lower back pain Canada 
#2 Rheumatoid arthritis United States 
#3 Prostate cancer United States 
#4 General oncology United States 
#5 General pediatrics Holland 
#6 Occupational medicine Denmark 
#7 Orthopedics United States 
#8 General practice, idiopathic pulmonary fibrosis England 
#9 Lung and heart transplant Canada 
#10 General oncology England 
 
Surveys and interviews:  
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Out of the ten participants, six members completed the survey and four participated in 60-minute 
telephone interviews. The survey centered around the nine key areas identified in the User’s Guide 
(see Table I). Respondents were encouraged to describe experiences, challenges and lessons learned 
in each of these areas. Additional questions included consideration of the timeframe for 
implementing PRO measures and key take-home messages. This survey was open ended, for 
example: ‘what were your purposes and goals for collecting PROs in clinical practice and what 
resources were available?’. Additional questions to consider for each main area were also presented 
beneath, for instance: ‘A. Was PRO data collection planned as a specific project or as part of daily 
routine?’ and ‘B. What additional resources would have been particularly helpful?’. These provided 
probes for participants to consider when providing their answers. In the telephone interviews, 
questions were asked using the survey template as a basis and in-depth notes or audio-recordings 
were taken by the interviewers. These telephone interviews adhered to the survey structure 
whereby the main question was asked, followed by probing using additional questions.   
Thematic data analysis: 
Completed case study templates and telephone interview notes were entered into a web-based 
mixed methods analysis program and database for coding (Dedoose.com). Through Dedoose, data 
was excerpted and coded according to the nine main topic areas from the User’s Guide. The code 
applications were reviewed and harmonized by at least two team members to assure reliability. 
Excerpted text was then exported into separate Excel spreadsheets corresponding to each of the 
nine topic areas. Individual members of the core working group each analyzed up to three of the 
nine sub-sections to identify and describe key themes [8]. Themes were generated through reading 
and re-reading the text and actively looking for patterns and meanings within the data. Finally, the 
thematic results of each subsection were reviewed and harmonized by at least two team members 
to assure reliability. This approach was consistent for both the survey data and the telephone 
interview data.  
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Results: 
From the surveys and telephone interviews, results were analyzed and summarized below according 
to the nine main topic areas with an additional section (10) focusing on key take-home messages.  
Section 1: Goals, resources and barriers to PRO collection  
Multiple objectives can be achieved through successful PRO measure implementation. When 
discussing implementation within clinical practice, respondents felt it was crucial that careful, 
inclusive organizational planning was the starting point. Prior to implementation, three key 
requirements were described including 1) goal setting for PRO collection, 2) identifying needed 
implementation resources, and 3) clearly communicating justifications for a PRO implementation to 
essential stakeholders.  
A range of PRO collection goals were described, including but not limited to, screening, monitoring, 
treatment evaluation and planning, aiding in treatment decision-making, and improving patient and 
provider satisfaction. One participant recalled that “The goal is to monitor and screen children with 
various chronic illnesses to be able to detect problems that arise at any early stage and to provide 
tailored interventions before the problems increase.” (#5).  
The availability of resources varied greatly between sites, with some describing limited resources, 
and others describing substantial support. This needs to be taken into consideration when planning 
PRO implementation, alongside taking into account limitations that may exist. The importance of not 
underestimating the amount of time and human resources required to establish and sustain PRO 
projects was discussed, as was the importance of training both at the start and throughout the 
implementation process. Following this, various forms of training were noted by respondents, 
ranging from short presentations to the development of a training program utilizing a behavioral 
change framework.   
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Barriers existed in the form of limited resources, and attention is needed to ensure these barriers do 
not prevent successful PRO implementation. For example, respondents highlighted that a lack of up-
front funding, or reliance on inconsistent funding sources, both presented a challenge. Similarly, the 
time-consuming nature of new electronic system development acted as a barrier.   
Other considerations in PRO planning were discussed, for instance the need to clearly communicate 
justifications for PRO implementation. Although the need for clear communication may seem self-
evident, respondents noted that efforts must be made before initiating a PRO implementation to 
ensure that all concerned stakeholders would derive value from the initiative. To ensure successful 
PRO implementation clinicians should agree on its purpose, and the measures should fill information 
gaps and meet the needs of all relevant stakeholders.  
Section 2: Groups of patients assessed 
Various groups of patients may be involved in PRO assessments, thus attention to language, physical 
and mental abilities, and age-based considerations were reported as being essential to consider. 
Respondents highlighted the importance of PRO data collection systems allowing patients to 
participate irrespective of their language abilities, their manual dexterity, their age and their comfort 
with using different technologies.  
One participant noted that although a previous study conducted had required that patients speak, 
read and write in English, that “it is extremely important to design future systems to allow 
participation among non-English speakers as well” (#3).  
Support that could be provided according to the needs of the patient was discussed, for instance the 
mode of data collection, such as the use of electronic tablets, or through availability of team 
members to offer support.  
Section 3: Selection of PRO measures 
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Determining the most appropriate PRO measure to collect the desired information was discussed by 
respondents. Four major themes emerged: 1) use of existing guidelines and conceptual models; 2) 
consideration of measurement properties; 3) measurement ease of use; and 4) engaging clinicians, 
patients, and other stakeholders in reaching consensus. 
The use of existing guidelines and conceptual models to assist in the selection of most appropriate 
PRO measures was noted. Respondents reported referring to a range of sources, including, the 
ISOQOL User’s Guide to Implementing PROs [7], the US Food and Drug Administration (FDA) Industry 
Guidance document [9], the European Medicines Agency (EMA) Reflections Paper [10], the 
International Classification of Functioning (ICF) [11], the Wilson and Cleary model [12], and the Triple 
Aim Framework [13]. Other respondents also mentioned use of the online PROMIS system 
(https://www.assessmentcenter.net/), as it provided a useful mode of assessment for their patient 
population. Additional evidence to inform PRO measure selection was also sought, for instance 
through conducting literature reviews, alongside consideration of other drivers such as the validity 
of the PRO instrument, its recall period, and its availability in multiple languages.  
Practical considerations were also discussed, such as ease of use of a measure. Measures were 
reportedly chosen by taking into account accessibility, length (i.e. number of items/time burden), 
response options, and ease of scoring. These factors are important to regard to prevent undue 
burden on patients and unnecessary data for clinicians.   
Respondents identified that reaching consensus on PRO selection was achieved through meetings 
and focus groups involving various stakeholders and patients. Clinicians felt that it was consistent 
with their role to contribute to the selection and implementation of PRO measures. 
Section 4: Timing of PRO administration 
Data collection was reported as being linked with clinical and/or research visits in all cases. In 
addition, the length of time for the collection of follow-up data was influenced by a variety of 
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factors, such as disease and/or treatment, the discretion of the care team, frequency of outpatient 
visits, and type of PRO measurement being used. For instance, one participant noted:  
“Completion of PROs depends on the purpose of data collection. For cancer studies, we typically 
collect for two weeks and then have a week off. If monitoring side effects then you may need to do it 
more frequently (weekly).” (#10) 
Section 5: PRO administration and scoring 
A myriad of alternative ways to administer and score PRO data exist. When considering this, three 
key themes emerged: 1) mode and format of data capture, 2) measure scoring, and 3) engagement 
with providers and patients. 
Multiple workflows for collecting PRO data from patients were reported. These included collections 
via web-based systems that patients could access at home with email prompts. Electronic collection 
of PRO data was discussed, and respondents noted many benefits such as error reductions, 
automatic scoring calculations, and management of data security measures. Paper-and-pencil 
administration was also referred to, with one respondent reporting higher response rates with this 
format of collection. However, many issues were discussed such as “time to transfer the data into 
our system” (#1), scans of scoring sheets being unreadable, and delays in clinic schedule if forms 
were not completed before the visit. Challenges with patients completing measures in the clinician’s 
office/waiting room or outpatient clinic settings were discussed, for instance: 
“You have to remember to print and have a copy before the patient walks in the clinic room. This is 
why screen prompts and having the questionnaire embedded in the EHR is valuable.” (#8) 
The involvement of multiple stakeholders to minimize the impact of PRO data collection on the 
clinician, e.g. medical assistants and nurse practitioners, was noted. The scoring of PRO measures 
was also considered, with discussions centering around electronic software scoring, and manual 
scoring. Challenges of manual scoring included:  
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“When done manually on paper, they [PRO measures] are often scanned into MR [medical record] 
and lost in the letters section and therefore not acted upon.” (#8) 
In relation to engagement with providers and patients, one respondent noted that PRO 
administration is most effective when the clinicians are ‘on board’ and consequently engaged in 
both the process and the initiative.  
Discussions around necessary care being taken when presenting new PRO measures to patients also 
occurred. Care must be taken to ensure patients understand the purpose of the PRO assessment and 
results, and to ensure that the value of PRO collection is fully communicated to them. Concerns 
around relying on primary health providers to refer patients to PRO systems were mentioned, 
specifically that such referral often did not occur. For instance, one respondent noted:  
“It depends on the clinic as well, and the provider, because if they really bought into it, I mean if a 
patient refuses – I've got some providers that go in there and sit down with them and say, this is 
really important, and finish with them. Whereas others were like ‘I don't care less if they do it.’” (#7) 
Section 6: Score interpretation and follow up 
Several challenges with interpretation of PRO measure results were discussed by respondents, for 
instance, the patient difficulty in interpreting scores and the lack of time for providers to review 
scores at every visit. Key themes relating to interpretation of PRO results emerged, including: 1) 
using standardized data, 2) representing data graphically, 3) using comparison data, 4) education 
and training, and 5) stakeholder consensus. 
Discussions arose surrounding the use of standardized data, with respondents referring to 
meaningful change in scores, the use of relating clinical variables to PRO results, and providing 
written information linking PRO feedback. The Companion Guide also covers respondent discussion 
of graphical representation of data to communicate PRO results. The use of comparison data to 
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inform interpretation was likewise discussed, this may include comparison to population scores, to 
others with the same disease, to expected scores, or to baseline data.   
Throughout the survey and interviews the importance of training to support clinicians and patients 
was highlighted, for instance:  
“Most people believe they understand measurement far better than they actually do.” (#2)  
Various PRO measures do not have standardized cut-points like a minimum clinically important 
difference (MCID) value defined in the literature, so respondents reported working with clinicians to 
reach consensus regarding key score changes. The importance of working together with different 
stakeholders was also considered, ensuring that PRO concepts are relevant to both patients and 
clinicians, to develop approaches to enhance the visual presentation of PRO data and its 
interpretation, and to determine clinical utility. 
Section 7: Presentation of results  
Following PRO collection and scoring, consideration turns to the presentation of the results with key 
plans needed for: 1) when and where, 2) how, 3) and to whom results are provided.    
Suggestions for when to present PRO results depend upon the respondent’s framework for clinical 
management. Discussions centered around presenting results in real time, in advance of clinic 
consultations, in quarterly team meetings, through electronic systems, and even presenting them at 
a ‘research day’ with patients and relatives present. In terms of how results are presented 
respondents discussed a manner of formats including graphs, electronic patient lists with significant 
scores highlighted, and electronic summary reports.   
PRO results were reportedly used by health providers to inform patient management. These results 
tended to be used by one specific clinician, however in some circumstances, multidisciplinary teams 
and wider groups of stakeholders were involved. In these situations, efforts were made to only show 
each team member scores relevant to their area of clinical expertise. Results were also reportedly 
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presented to patients or to patients’ caregivers, with one respondent emphasizing the need for 
additional training to support clinicians in communicating these results. A further respondent asked: 
“How do we present PRO data to patients themselves, especially if they see their scores getting 
worse?” (#10) 
Section 8: Responding to issues 
The appropriate response to issues identified through PRO assessment was discussed by 
respondents. For example, the importance of linking a patient’s data to clinical decision-making. In 
one case, a respondent explained that their system aids in care management as it enables clinicians 
to determine whether the patient requires a visit or consultation, and what symptoms are a priority 
in terms of treatment and management. This is processed by an automatic algorithm and assigns 
patients by a color depending on whether contact is needed.  
It was noted that following issues identified in PRO assessments, a referral can be made. For 
instance, “if necessary, the patient or parent can be referred to the psychosocial services 
department” (#5). 
Section 9: Evaluation of PRO value 
When evaluating the impact of PRO measure application in clinical practice, respondents discussed 
both formal and informal evaluations. Formal evaluations described by respondents included an 
exploration of providing standardized PRO information in oncology care, the use of tele-completed 
PRO measures within an occupational medicine clinic, routine, annual evaluations of a pediatric PRO 
system, and clinician interviews as part of a chronic pain management program. Informal evaluations 
were also described, for instance the reporting of positive responses from clinicians and patients. 
One respondent reported for a clinician: 
“He loves being able to have these simple easy reports and watch the trends of his patients.” (#7) 
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However, skepticism among some providers was also described, particularly those who are new to 
the concept of PRO application. The importance of future research to gain better understanding of 
PRO information use in informing decision-making was discussed.   
Section 10: Key take-home messages 
Respondents were asked to provide key take-home messages for using PRO measures in clinical 
practice. Many benefits were reported, and crucial messages included the idea that PRO 
implementation needs ease of use, ease of access and a clinical determinant. PRO measures need to 
be regarded as the center of care, must address gaps in information needs, and the feedback needs 
to be actionable.  
The importance of engaging stakeholders was emphasized, as support is needed from all those 
involved, including administrative support, clinicians, and patients. Respondents also considered the 
need for available adequate institutional resources to support PRO assessment. Three respondents 
discussed the importance of considering the way in which PRO data will be integrated into the EHR 
and the organizations technical infrastructure. The timeframe of implementation was also discussed, 
with one respondent estimating it took around three months to carry out a pilot. An additional 
respondent suggested that the entire process from conceptualization to implementation took about 
three years, and a further respondent estimated that the process took a number of years.  
Conclusions:  
The use of PRO measures in clinical practice is constantly developing and evolving with time. 
Challenges faced by health care providers highlight the need for comprehensive guidance to support 
PRO assessment in clinical practice. The Companion Guide was designed to allow those working in 
the field of quality of life research to gain insight and learn from the case studies presented. The 
intention was to provide a concise, user-friendly guide to contextualize the information provided 
within the User’s Guide using real-world examples from various clinical areas. 
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The ten case studies from these clinical sites allow the Companion Guide to outline some of the 
potential barriers and opportunities when embarking on a PRO program in clinical practice, covering 
a range of patient populations, specialties and countries. This paper provides a brief overview of the 
information presented in the Companion Guide, reflecting on the experiences of PRO 
implementation in practice. From this, researchers can access the full Companion Guide to gain 
further case study details.  
A potential limitation with this work is that advances may have occurred since the case studies were 
presented; for instance, advances in technology may have provided opportunities for improving 
practice, solutions to current challenges, or potentially presented additional obstacles that were not 
known when this companion guide was initiated. Thus, the aspiration is that the Companion Guide 
will continue as a living repository for PRO researchers and practitioners and will be updated as new 
solutions become available, new challenges are faced, and new case studies are available to reflect 
upon. 
The full Companion Guide, and User’s Guide, can be accessed at http://www.isoqol.org/research-
publications-landing-page/isoqol-publications. ISOQOL also offers a number of other education 
courses, webinars and training – these can be accessed at http://www.isoqol.org/education-events.   
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